Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A non-resolving inflammation results in a chronic inflammatory response, characteristic of atherosclerosis, abdominal aortic aneurysms and several other cardiovascular diseases. Restoring the levels of specialized proresolving mediators to drive the chronic cardiovascular inflammation toward resolution is emerging as a novel therapeutic principle. The lipid mediators lipoxins and resolvins exert their proresolving actions through specific G-protein coupled receptors (GPCR). So far, four GPCR have been identified as the receptors for lipoxin A4 and the D- and E-series of resolvins, namely ALX/FPR2, DRV1/GPR32, DRV2/GPR18, and ERV1/ChemR23. At the same time, other pro-inflammatory ligands also activate some of these receptors. Recent studies of genetic targeting of these receptors in atherosclerotic mouse strains have revealed a major role for proresolving receptors in atherosclerosis. The present review addresses the complex pharmacology of these four proresolving GPCRs with focus on their therapeutic implications and opportunities for inducing the resolution of inflammation in cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 1×
“When referring to RvE1 ligation with ChemR23, the receptor has been denoted ERV1 (Bäck et al., 2014; Lopez-Vicario et al., 2017; Sima et al., 2017; LagunaFernandez et al., 2018), and will in this review be referred to as ERV1/ChemR23.”
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453
Infection regulates pro-resolving mediators that lower antibiotic requirements
Chiang, N., Fredman, G., Bäckhed, F., Oh, S. F., Vickery, T., Schmidt, B. A., & Serhan, C. N. (2012) · Nature · doi:10.1038/nature11042 · Cited by 664
van Gils, J. M., Derby, M. C., Fernandes, L. R., Ramkhelawon, B., Ray, T. D., Rayner, K. J., Parathath, S., Distel, E., Feig, J. L., Alvarez-Leite, J. I., et al. (2012) · Nature Immunology · doi:10.1038/ni.2205 · Cited by 365
MicroRNAs in resolution of acute inflammation: identification of novel resolvin Dl‐miRNA circuits
Recchiuti, A., Krishnamoorthy, S., Fredman, G., Chiang, N., & Serhan, C. N. (2011) · The FASEB Journal · doi:10.1096/fj.10-169599 · Cited by 292 · cited 1×
“DRV1/GPR32 is expressed in human macrophages (Schmid et al., 2016) in which it increases phagocytosis (Chiang et al., 2012) and miRNAs involved in proresolving signaling (Recchiuti et al., 2011; Recchiuti and Serhan, 2012) in response to RvD1.”
El Kebir, D., Gjorstrup, P., & Filep, J. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206641109 · Cited by 289 · cited 1×
“RvE1 limits neutrophil infiltration by means of promoting phagocytosis-induced neutrophil apoptosis and efferocytosis (El Kebir et al., 2012).”
Resolvin D1 Receptor Stereoselectivity and Regulation of Inflammation and Proresolving MicroRNAs
Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., & Serhan, C. N. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.01.028 · Cited by 283 · cited 1×
“, 2013a), Resolvin D1 (RvD1) (Krishnamoorthy et al., 2012), and Resolvin D3 (Arnardottir et al.”
Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis
Ohira, T., Arita, M., Omori, K., Recchiuti, A., Van Dyke, T. E., & Serhan, C. N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.044131 · Cited by 278
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Bäck, M., Powell, W. S., Dahlén, S., Drazen, J. M., Evans, J. F., Serhan, C. N., Shimizu, T., Yokomizo, T., & Rovati, G. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12665 · Cited by 217
Self-citationHo, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H. K., Pande, R., Creager, M. A., Serhan, C. N., & Conte, M. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091082 · Cited by 204
Cited by
Macrophages and the maintenance of homeostasis
Mosser, D. M., Hamidzadeh, K., & Goncalves, R. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00541-3 · Cited by 505
Specialized pro-resolving mediator network: an update on production and actions
Chiang, N., & Serhan, C. N. (2020) · Essays in Biochemistry · doi:10.1042/ebc20200018 · Cited by 438
Dobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 268
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function
Brennan, E., Kantharidis, P., Cooper, M. E., & Godson, C. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00454-y · Cited by 262
Suzumura, A., Terao, R., & Kaneko, H. (2020) · Antioxidants · doi:10.3390/antiox9100920 · Cited by 44
“Currently, several receptors have been identified that recognize members of the D- and E-series of resolvins, including, D resolvin receptor 1 (DRV1)/GPR32, lipoxin A4 receptor/formyl peptide receptor 2, DRV2/GPR18, resolvin E1 receptor/ChemR23, and leukotriene B4 receptor 1 (BLT1) [63,64].”
BackgroundThe lipid paradox in neuroprogressive disorders: Causes and consequences
Morris, G., Berk, M., Walder, K., O’Neil, A., Maes, M., & Puri, B. K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.017 · Cited by 17
Metadata
- Authors
- Pirault, J., & Bäck, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-14
- Volume
- 9
- Pages
- 1273-1273
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2901773763
- Cited by
- 165
- References
- 19
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.